Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers
Standard
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. / Oehrlein, Katharina; Langer, Christian; Sturm, Isrid; Pönisch, Wolfram; Hahn-Ast, Corinna; Kuhn, Sigrid; Weisel, Katja C.
in: CL LYMPH MYELOM LEUK, Jahrgang 12, Nr. 3, 06.2012, S. 191-6.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers
AU - Oehrlein, Katharina
AU - Langer, Christian
AU - Sturm, Isrid
AU - Pönisch, Wolfram
AU - Hahn-Ast, Corinna
AU - Kuhn, Sigrid
AU - Weisel, Katja C
N1 - Copyright © 2012 Elsevier Inc. All rights reserved.
PY - 2012/6
Y1 - 2012/6
N2 - UNLABELLED: Retrospective multicenter analysis of 26 patients with multiple myeloma to assess the efficacy and toxicity of relapse treatment with lenalidomide/dexamethasone in renal-function impairment. Analysis showed myeloma overall response rate of 84%, with 42% of patients with improvement of renal function. Lenalidomide/dexamethasone is highly effective, with acceptable toxicity in the renally impaired patient group.PURPOSE: Renal impairment is one of the main complications of multiple myeloma associated with unfavorable prognosis. Lenalidomide in combination with dexamethasone is an effective treatment of relapsed and/or refractory multiple myeloma and may be used in patients with myeloma and with renal insufficiency with appropriate dose adaption according to creatinine clearance (CLCr). However, there are limited data on the use of this regimen in patients with myeloma and with impaired renal function.PATIENTS AND METHODS: We report on 26 patients, in 4 German centers, with impaired renal function and relapsed and/or refractory multiple myeloma who were treated with lenalidomide/dexamethasone-based regimens; we retrospectively analyzed their data.RESULTS: All 26 patients had a CLCr < 60 mL/min. Six patients were permanently or temporarily dialysis dependent. Overall response rate (ie, at least a partial response) was 84%. The rate of renal response (at least minor renal response) was 42%, with 6 patients achieving a complete renal response. A median time of 28 days was documented until first response. Six patients had grade 3/4 thromboembolic events; all but one of these patients received prophylaxis with acetylsalicylic acid.CONCLUSION: Lenalidomide-based treatment is highly effective and is an attractive treatment option in patients with multiple myeloma with impaired renal function. In this analysis, renal function was improved in a substantial proportion of patients.
AB - UNLABELLED: Retrospective multicenter analysis of 26 patients with multiple myeloma to assess the efficacy and toxicity of relapse treatment with lenalidomide/dexamethasone in renal-function impairment. Analysis showed myeloma overall response rate of 84%, with 42% of patients with improvement of renal function. Lenalidomide/dexamethasone is highly effective, with acceptable toxicity in the renally impaired patient group.PURPOSE: Renal impairment is one of the main complications of multiple myeloma associated with unfavorable prognosis. Lenalidomide in combination with dexamethasone is an effective treatment of relapsed and/or refractory multiple myeloma and may be used in patients with myeloma and with renal insufficiency with appropriate dose adaption according to creatinine clearance (CLCr). However, there are limited data on the use of this regimen in patients with myeloma and with impaired renal function.PATIENTS AND METHODS: We report on 26 patients, in 4 German centers, with impaired renal function and relapsed and/or refractory multiple myeloma who were treated with lenalidomide/dexamethasone-based regimens; we retrospectively analyzed their data.RESULTS: All 26 patients had a CLCr < 60 mL/min. Six patients were permanently or temporarily dialysis dependent. Overall response rate (ie, at least a partial response) was 84%. The rate of renal response (at least minor renal response) was 42%, with 6 patients achieving a complete renal response. A median time of 28 days was documented until first response. Six patients had grade 3/4 thromboembolic events; all but one of these patients received prophylaxis with acetylsalicylic acid.CONCLUSION: Lenalidomide-based treatment is highly effective and is an attractive treatment option in patients with multiple myeloma with impaired renal function. In this analysis, renal function was improved in a substantial proportion of patients.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Agents
KW - Dexamethasone
KW - Female
KW - Humans
KW - Lenalidomide
KW - Male
KW - Middle Aged
KW - Multiple Myeloma
KW - Recurrence
KW - Renal Insufficiency
KW - Retrospective Studies
KW - Thalidomide
KW - Treatment Outcome
KW - Journal Article
KW - Multicenter Study
KW - Research Support, Non-U.S. Gov't
U2 - 10.1016/j.clml.2012.01.001
DO - 10.1016/j.clml.2012.01.001
M3 - SCORING: Journal article
C2 - 22341857
VL - 12
SP - 191
EP - 196
JO - CL LYMPH MYELOM LEUK
JF - CL LYMPH MYELOM LEUK
SN - 2152-2650
IS - 3
ER -
